Loading...

Telesis Bio, Inc.

TBIO•NASDAQ
Healthcare
Medical - Devices
$0.30
$0.20(200.00%)

Telesis Bio, Inc. (TBIO) Stock Overview

Explore Telesis Bio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.4/100

Key Financials

Market Cap532.8K
P/E Ratio-0.01
EPS (TTM)$-30.42
ROE-2.80%

AI Price Forecasts

1 Week$0.01
1 Month$0.03
3 Months$0.00
1 Year Target$0.01

TBIO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Telesis Bio, Inc. (TBIO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.01 and a market capitalization of 532.8K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for TBIOStats details for TBIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for TBIOAnalyst Recommendations details for TBIO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

CEO

Eric Esser

Employees

39

Headquarters

29 Hartwell Ave, Lexington, MA

Founded

2021

Frequently Asked Questions

;